PL1866324T3 - Fosforamidanowe pochodne związków nukleozydowych do stosowania przy leczeniu raka - Google Patents

Fosforamidanowe pochodne związków nukleozydowych do stosowania przy leczeniu raka

Info

Publication number
PL1866324T3
PL1866324T3 PL06710096T PL06710096T PL1866324T3 PL 1866324 T3 PL1866324 T3 PL 1866324T3 PL 06710096 T PL06710096 T PL 06710096T PL 06710096 T PL06710096 T PL 06710096T PL 1866324 T3 PL1866324 T3 PL 1866324T3
Authority
PL
Poland
Prior art keywords
cancer
treatment
nucleoside compounds
phosphoramidate derivatives
compounds
Prior art date
Application number
PL06710096T
Other languages
English (en)
Inventor
Christopher Mcguigan
Kenneth Mills
Costantino Congiatu
Original Assignee
Nucana Biomed Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nucana Biomed Ltd filed Critical Nucana Biomed Ltd
Publication of PL1866324T3 publication Critical patent/PL1866324T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL06710096T 2005-03-21 2006-03-16 Fosforamidanowe pochodne związków nukleozydowych do stosowania przy leczeniu raka PL1866324T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0505781.5A GB0505781D0 (en) 2005-03-21 2005-03-21 Chemical compounds
PCT/GB2006/000932 WO2006100439A1 (en) 2005-03-21 2006-03-16 Phosphoramidate derivatives of nucleoside compounds for use in the treatment of cancer
EP06710096A EP1866324B1 (en) 2005-03-21 2006-03-16 Phosphoramidate derivatives of nucleoside compounds for use in the treatment of cancer

Publications (1)

Publication Number Publication Date
PL1866324T3 true PL1866324T3 (pl) 2010-12-31

Family

ID=34531603

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06710096T PL1866324T3 (pl) 2005-03-21 2006-03-16 Fosforamidanowe pochodne związków nukleozydowych do stosowania przy leczeniu raka

Country Status (20)

Country Link
US (1) US8263575B2 (pl)
EP (1) EP1866324B1 (pl)
JP (2) JP5345381B2 (pl)
CN (2) CN101175763A (pl)
AT (1) ATE471334T1 (pl)
AU (1) AU2006226182C1 (pl)
BR (1) BRPI0609704B8 (pl)
CA (1) CA2602324C (pl)
CY (1) CY1111538T1 (pl)
DE (1) DE602006014949D1 (pl)
DK (1) DK1866324T3 (pl)
ES (1) ES2348741T3 (pl)
GB (1) GB0505781D0 (pl)
IL (1) IL186104A (pl)
MX (1) MX2007011666A (pl)
PL (1) PL1866324T3 (pl)
PT (1) PT1866324E (pl)
SI (1) SI1866324T1 (pl)
WO (1) WO2006100439A1 (pl)
ZA (1) ZA200709011B (pl)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012216500B2 (en) * 2006-11-24 2013-06-20 Katholieke Universiteit Leuven Nucleoside aryl phosphoramidates and their use as anti-viral agents for the treatment of hepatitis C virus
GB0623493D0 (en) 2006-11-24 2007-01-03 Univ Cardiff Chemical compounds
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
WO2010075549A2 (en) 2008-12-23 2010-07-01 Pharmasset, Inc. Nucleoside phosphoramidates
CN102325783A (zh) 2008-12-23 2012-01-18 法莫赛特股份有限公司 嘌呤核苷的合成
US8551973B2 (en) 2008-12-23 2013-10-08 Gilead Pharmasset Llc Nucleoside analogs
CN102348712A (zh) 2009-01-09 2012-02-08 卡迪夫大学学院顾问有限公司 用于治疗病毒感染的鸟苷核苷类化合物的磷酰胺酯衍生物
SI3290428T1 (sl) 2010-03-31 2022-01-31 Gilead Pharmasset Llc Tableta, ki obsega kristalinični (S)-izopropil 2-(((S)-(((2R,3R,4R,5R) -5-(2,4-diokso-3,4-dihidropirimidin-1(2H)-il)-4-fluoro-3-hidroksi-4- metiltetrahidrofuran-2-il)metoksi)(fenoksi)fosforil)amino)propanoat
GB201016855D0 (en) * 2010-10-06 2010-11-17 Nucana Biomed Ltd Chemical compounds
EP2658857B1 (en) * 2010-12-29 2016-11-02 Inhibitex, Inc. Substituted purine nucleosides, phosphoroamidate and phosphorodiamidate derivatives for treatment of viral infections
WO2012094248A1 (en) * 2011-01-03 2012-07-12 Nanjing Molecular Research, Inc. O-(substituted benzyl) phosphoramidate compounds and therapeutic use
PL3447061T3 (pl) * 2011-03-01 2022-01-31 NuCana plc Farmaceutyczna formulacja zawierająca pochodną fosforoamidynianową 5-fluoro-2'-deoksyurydyny do zastosowania w leczeniu nowotworu
US9085599B2 (en) 2011-03-16 2015-07-21 Enanta Pharmaceuticals, Inc. 2′allene-substituted nucleoside derivatives
ES2725491T3 (es) * 2012-11-16 2019-09-24 Univ College Cardiff Consultants Ltd Mezcla de RP/SP gemcitabina-[fenil-(benciloxi-L-alaninil)]-fosfato
WO2014197578A1 (en) 2013-06-05 2014-12-11 Idenix Pharmaceuticals, Inc. 1',4'-thio nucleosides for the treatment of hcv
WO2015081133A2 (en) * 2013-11-27 2015-06-04 Idenix Pharmaceuticals, Inc. Nucleotides for the treatment of liver cancer
MX2016015568A (es) * 2014-05-28 2017-07-04 Idenix Pharmaceuticals Llc Derivados de nucleosidos para el tratamiento del cancer.
WO2015181624A2 (en) * 2014-05-28 2015-12-03 Idenix Pharmaceuticals, Inc Nucleoside derivatives for the treatment of cancer
SI3224268T1 (sl) * 2014-11-28 2019-10-30 NuCana plc Novi 2' in/ali 5' amino kislinski ester fosforamidat 3'-deoksi adenozinski derivati kot proti-rakaste spojine
US10745435B2 (en) * 2015-11-16 2020-08-18 Cerecor, Inc. Nucleic acid prodrugs
GB201522764D0 (en) * 2015-12-23 2016-02-03 Nucana Biomed Ltd Formulations of phosphate derivatives
GB201609601D0 (en) * 2016-06-01 2016-07-13 Nucana Biomed Ltd Phosphoramidate compounds
GB201609602D0 (en) * 2016-06-01 2016-07-13 Nucuna Biomed Ltd Chemical compounds
GB201609600D0 (en) 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
US10711029B2 (en) 2016-07-14 2020-07-14 Atea Pharmaceuticals, Inc. Beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-c-substituted-4′fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
PT3512863T (pt) 2016-09-07 2022-03-09 Atea Pharmaceuticals Inc Nucleótidos de purina 2'-substituídos-n6-substituídos para tratamento de vírus de rna
US11202792B2 (en) * 2016-10-12 2021-12-21 Georgetown University CD99 inhibitors and their uses
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
GB201715011D0 (en) 2017-09-18 2017-11-01 Nucana Biomed Ltd Floxuridine synthesis
GB201720279D0 (en) 2017-12-05 2018-01-17 Nucana Biomed Ltd Anticancer compounds
GB201904544D0 (en) 2019-04-01 2019-05-15 NuCana plc Anticancer compounds
WO2021173713A1 (en) 2020-02-27 2021-09-02 Atea Pharmaceuticals, Inc. Highly active compounds against covid-19
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
CN113549076B (zh) * 2021-07-23 2022-12-06 中国药科大学 一种多取代嘌呤类化合物及其制备方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR880000094B1 (ko) 1984-12-07 1988-02-23 보령제약 주식회사 뉴클레오시드 유도체의 제조방법
CA2004695C (en) 1988-12-12 1999-08-10 Rosanne Bonjouklian Phospholipid nucleosides
DE4418690A1 (de) * 1994-05-28 1996-01-11 Boehringer Mannheim Gmbh Neue Lipidester von Nucleosid-Monophosphaten und deren Verwendung als immunsuppressive Arzneimittel
GB9505025D0 (en) * 1995-03-13 1995-05-03 Medical Res Council Chemical compounds
CA2675757C (en) * 1995-04-21 2011-03-15 University Of South Florida Immunopotentiating inosine monophosphate 5'-nucleotidase resistant derivatives and uses thereof
JP3761958B2 (ja) 1996-03-12 2006-03-29 彰 松田 ３′−カルバモイルアルキルヌクレオシド誘導体
EP1045897B1 (en) * 1998-01-23 2002-01-30 Newbiotics Inc. Enzyme catalyzed therapeutic agents
GB9821058D0 (en) * 1998-09-28 1998-11-18 Univ Cardiff Chemical compound
JP4768909B2 (ja) 2000-09-29 2011-09-07 扶桑薬品工業株式会社 トポイソメラーゼ阻害剤
US20030073618A1 (en) 2001-02-08 2003-04-17 Kozhemyakin Leonid A. Compounds comprising disulfide-containing peptides and nitrogenous bases, and medical uses thereof
DE10108851A1 (de) * 2001-02-23 2002-09-12 Resprotect Gmbh Verwendung von 5'-substituierten Nukleosiden und/oder deren Prodrugs zur resistenzfreien Therapie von Infektionskrankheiten
KR20050059975A (ko) 2001-06-22 2005-06-21 파마셋 인코포레이티드 β-2'- 또는 3'-할로뉴클레오시드
GB0317009D0 (en) * 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
GB0401088D0 (en) 2004-01-19 2004-02-18 Univ Cardiff Phosphoramidate derivatives
CN1972696B (zh) * 2004-06-24 2010-08-11 默沙东公司 用于治疗rna依赖性rna病毒感染的核苷氨基磷酸芳基酯
EP1928475B1 (en) * 2005-08-15 2018-05-23 Riboscience LLC Antiviral phosphoramidates of 4'-c-azido-substituted pronucleotides

Also Published As

Publication number Publication date
BRPI0609704B8 (pt) 2021-09-28
AU2006226182C1 (en) 2012-06-14
ATE471334T1 (de) 2010-07-15
IL186104A (en) 2013-06-27
AU2006226182A1 (en) 2006-09-28
JP5345381B2 (ja) 2013-11-20
CA2602324C (en) 2015-02-24
EP1866324B1 (en) 2010-06-16
MX2007011666A (es) 2007-11-14
EP1866324A1 (en) 2007-12-19
CA2602324A1 (en) 2006-09-28
GB0505781D0 (en) 2005-04-27
DK1866324T3 (da) 2010-09-27
PT1866324E (pt) 2010-09-16
SI1866324T1 (sl) 2010-10-29
CN103936807A (zh) 2014-07-23
US20090215715A1 (en) 2009-08-27
AU2006226182B2 (en) 2011-09-01
US8263575B2 (en) 2012-09-11
JP5863702B2 (ja) 2016-02-17
JP2013173786A (ja) 2013-09-05
DE602006014949D1 (de) 2010-07-29
BRPI0609704B1 (pt) 2020-12-01
ZA200709011B (en) 2009-01-28
JP2008533191A (ja) 2008-08-21
BRPI0609704A2 (pt) 2010-04-20
ES2348741T3 (es) 2010-12-13
CN101175763A (zh) 2008-05-07
CY1111538T1 (el) 2015-08-05
WO2006100439A1 (en) 2006-09-28
IL186104A0 (en) 2008-01-20

Similar Documents

Publication Publication Date Title
ZA200709011B (en) Phosphoramidate derivatives of nucleoside compounds for use in the treatment of cancer
SG164368A1 (en) Treatment of cancer
MY146112A (en) Long-term feed - cancer patient
MX354099B (es) Antagonistas de activina-actriia y usos para tratar o prevenir cancer de mama.
TW200612918A (en) Lonidamine analogs
ZA201800056B (en) Nicotinamide riboside and pterostilbene compositions and methods for treatment of skin disorders
IL190796A0 (en) Compositions and their uses for gene therapy of bone conditions
MX2010001821A (es) Derivados de purina para uso en el tratamiento de enfermedades relacionadas con fap.
PH12015500485A1 (en) Phosphoramidate derivatives of 5 - fluoro - 2` - deoxyuridine for use in the treatment of cancer
MX2009010899A (es) Prediccion de la supervivencia al post-tratamiento en pacientes de cancer con micro-rnas.
TW200716141A (en) Compositions and methods for treatment for neoplasms
TW200733166A (en) Ion sources, systems and methods
BRPI0611670A2 (pt) método para o tratamento ou prevenção de câncer em um indivíduo
TW200637522A (en) Skin treatment articles and methods
WO2007064872A3 (en) Urea compounds useful in the treatment of cancer
MY147247A (en) Organic compounds and their uses
MX2009012228A (es) Compuesto de triazolil aminopirimidina.
WO2009009034A3 (en) Methods and compositions useful in the treatment of mucositis
NO20074780L (no) Heterocyklylamidsubstituerte imidazoler
DE602005015329D1 (de) Rutheniumkomplexe zur krebsbehandlung
EA200971067A1 (ru) Триазолиламинопиримидиновые соединения
EP2099458A4 (en) COMPOUNDS AND METHODS FOR IMAGING AND THERAPY OF ENZYME-MEDIATED TUMORS
WO2009074253A3 (en) Clofarabine dietherphospholipid derivatives
MY166063A (en) Intravenous antiviral treatments
UA101379C2 (en) Amidophenoxyindazoles useful in the treatment of cancer